Skip to main content

Advertisement

SpringerLink
Log in

Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Biochemical failure after curative-intent therapies is an increasingly common dilemma confronting patients and physicians. No definition of biochemical failure exists that can be applied to all forms of treatment and that is not to some degree affected by the follow-up interval, pretreatment prognostic factors, or the frequency of prostatic-specific antigen (PSA) testing. Available imaging techniques lack sensitivity in detection of occult micrometastases. Prognostic factors such as tumor characteristics and PSA kinetics should be considered when recommending second-line therapies. For those patients with suspected localized recurrence, second-line treatment with salvage therapies may provide long-term disease control. Hormonal therapy, although most commonly employed for PSA recurrence, is of palliative benefit only. Currently, the most appropriate therapeutic intervention for asymptomatic patients with evidence of biochemical failure remains undefined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10–30.

    Article  PubMed  Google Scholar 

  2. Moul JW: Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol 2003, 21:292–304. This paper provides an excellent overview of the diagnostic and therapeutic dilemmas confronting physicians caring for patients with biochemical relapse. In addition, important tumor and PSA variables to consider when making decisions regarding management are summarized.

    PubMed  Google Scholar 

  3. Djavan B, Moul JW, Zlotta A, et al.: PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur Urol 2003, 43:12–27.

    Article  PubMed  Google Scholar 

  4. Ward JF, Moul JW: Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol 2005, 15:187–195.

    Article  PubMed  Google Scholar 

  5. D’Amico AV, Moul J, Carroll PR, et al.: Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostatespecific antigen era. J Clin Oncol 2003, 21:2163–2172.

    Article  PubMed  Google Scholar 

  6. Ravery V: The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 1999, 17:127–129.

    PubMed  CAS  Google Scholar 

  7. Partin AW, Pearson JD, Landis PK, et al.: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994, 43:649–659.

    Article  PubMed  CAS  Google Scholar 

  8. Lange PH, Ercole CJ, Lightner DJ, et al.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989, 141:873–879.

    PubMed  CAS  Google Scholar 

  9. Amling CL, Bergstralh EJ, Blute ML, et al.: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001, 165:1146–1151.

    Article  PubMed  CAS  Google Scholar 

  10. Djavan B, Waldert M, Ghawidel C, et al.: Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 2004, 14:45–50.

    Article  PubMed  Google Scholar 

  11. Stephenson AJ, Eastham JA: Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005, 23:8198–8203. A comprehensive and timely review of control rates and complications associated with salvage RP after radiation therapy.

    Article  PubMed  Google Scholar 

  12. Rosser CJ, Kuban DA, Levy LB, et al.: Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 2002, 168:2001–2005.

    Article  PubMed  CAS  Google Scholar 

  13. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997, 37:1035–1041.

  14. Horwitz EM, Uzzo RG, Hanlon AL, et al.: Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol 2003, 169:2153–2157; discussion 2157–2159.

    Article  PubMed  Google Scholar 

  15. Kuban DA, Thames HD, Shipley WU: Defining recurrence after radiation for prostate cancer. J Urol 2005, 173:1871–1878.

    Article  PubMed  Google Scholar 

  16. Pound CR, Partin AW, Eisenberger MA, et al.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591–1597. In this landmark study, the natural progression of prostate cancer of 1997 patients with PSA-only relapse after RP who do not undergo initial treatment is characterized.

    Article  PubMed  CAS  Google Scholar 

  17. Jhaveri FM, Zippe CD, Klein EA, et al.: Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999, 54:884–890.

    Article  PubMed  CAS  Google Scholar 

  18. D’Amico AV, Moul JW, Carroll PR, et al.: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003, 95:1376–1383.

    PubMed  Google Scholar 

  19. Patel DA, Presti JC, Jr., McNeal JE, et al.: Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 2005, 23:6157–6162.

    Article  PubMed  Google Scholar 

  20. Patel A, Dorey F, Franklin J, et al.: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997, 158:1441–1445.

    Article  PubMed  CAS  Google Scholar 

  21. D’Amico AV, Cote K, Loffredo M, et al.: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002, 20:4567–4573.

    Article  PubMed  Google Scholar 

  22. Cher ML, Bianco FJ, Jr., Lam JS, et al.: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998, 160:1387–1391.

    Article  PubMed  CAS  Google Scholar 

  23. Kane CJ, Amling CL, Johnstone PA, et al.: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003, 61:607–611.

    Article  PubMed  Google Scholar 

  24. Okotie OT, Aronson WJ, Wieder JA, et al.: Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004, 171:2260–2264.

    Article  PubMed  Google Scholar 

  25. Quintana JC, Blend MJ: The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med 2000, 25:33–40.

    Article  PubMed  CAS  Google Scholar 

  26. Kahn D, Williams RD, Manyak MJ, et al.: 111Indiumcapromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 1998, 159:2041–2046; discussion 2046–2047.

    Article  PubMed  CAS  Google Scholar 

  27. Levesque PE, Nieh PT, Zinman LN, et al.: Radiolabeled monoclonal antibody indium 111-labeled CY T-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998, 51:978–984.

    Article  PubMed  CAS  Google Scholar 

  28. Raj GV, Partin AW, Polascik TJ: Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002, 94:987–996.

    Article  PubMed  Google Scholar 

  29. Hinkle GH, Burgers JK, Neal CE, et al.: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998, 83:739–747.

    Article  PubMed  CAS  Google Scholar 

  30. Kahn D, Williams RD, Haseman MK, et al.: Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998, 16:284–289.

    PubMed  CAS  Google Scholar 

  31. Thomas CT, Bradshaw PT, Pollock BH, et al.: Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003, 21:1715–1721.

    Article  PubMed  CAS  Google Scholar 

  32. Ward JF, Zincke H, Bergstralh EJ, et al.: Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004, 172:2244–2248.

    Article  PubMed  Google Scholar 

  33. Stephenson AJ, Shariat SF, Zelefsky MJ, et al.: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004, 291:1325–1332. This retrospective review of 501 patients receiving salvage radiotherapy for rising PSA after RP identifies cancer-specific variables associated with long-term responses.

    Article  PubMed  CAS  Google Scholar 

  34. Garg MK, Tekyi-Mensah S, Bolton S, et al.: Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998, 51:998–1002.

    Article  PubMed  CAS  Google Scholar 

  35. MacDonald OK, Schild SE, Vora S, et al.: Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?. Urology 2004, 64:760–764.

    Article  PubMed  Google Scholar 

  36. Cadeddu JA, Partin AW, DeWeese TL, et al.: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998, 159:173–177; discussion 177-178.

    Article  PubMed  CAS  Google Scholar 

  37. Bianco FJ, Jr., Scardino PT, Stephenson AJ, et al.: Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:448–453.

    Article  PubMed  Google Scholar 

  38. Gheiler EL, Tefilli MV, Tiguert R, et al.: Predictors for maximal outcome in patients undergoing salvage surgery for radiorecurrent prostate cancer. Urology 1998, 51:789–795.

    Article  PubMed  CAS  Google Scholar 

  39. Amling CL, Lerner SE, Martin SK, et al.: Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999, 161:857–862;discussion 862–853.

    Article  PubMed  CAS  Google Scholar 

  40. Garzotto M, Wajsman Z: Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 1998, 159:950–954; discussion 954–955.

    Article  PubMed  CAS  Google Scholar 

  41. Izawa JI, Ajam K, McGuire E, et al.: Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer. J Urol 2000, 164:1978–1981.

    Article  PubMed  CAS  Google Scholar 

  42. Ghafar MA, Johnson CW, De La Taille A, et al.: Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol 2001, 166:1333–1337;discussion 1337–1338.

    Article  PubMed  CAS  Google Scholar 

  43. Han KR, Cohen JK, Miller RJ, et al.: Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 2003, 170:1126–1130.

    Article  PubMed  Google Scholar 

  44. Grado GL, Collins JM, Kriegshauser JS, et al.: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999, 53:2–10.

    Article  PubMed  CAS  Google Scholar 

  45. Sylvester J, Grimm P, Blasco J, et al.: The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology 2001, 58:65–70.

    Article  PubMed  CAS  Google Scholar 

  46. Duchesne GM, Millar JL, Moraga V, et al.: What to do for prostate cancer patients with a rising PSA?-A survey of Australian practice. Int J Radiat Oncol Biol Phy 2003, 55:986–991.

    Article  Google Scholar 

  47. Mehta SS, Lubeck DP, Sadetsky N, et al.: Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J Urol 2004, 171:215–219.

    Article  PubMed  Google Scholar 

  48. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet 2000, 355:1491–1498. A collaborative meta-analysis of 27 randomized trials evaluating maximum androgen ablation including 8275 men as compared with androgen suppression alone for patients with metastatic and locally advanced prostate cancer.

    Article  Google Scholar 

  49. Caubet JF, Tosteson TD, Dong EW, et al.: Maximum androgen blockade in advanced prostate cancer: a metaanalysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997, 49:71–78.

    Article  PubMed  CAS  Google Scholar 

  50. Bennett CL, Tosteson TD, Schmitt B, et al.: Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using fiutamide. Prostate Cancer Prostatic Dis 1999, 2:4–8.

    Article  PubMed  Google Scholar 

  51. Bertagna C, De Gery A, Hucher M, et al.: Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 1994, 73:396–402.

    PubMed  CAS  Google Scholar 

  52. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997, 79:235–246.

    Google Scholar 

  53. Messing EM, Manola J, Sarosdy M, et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781–1788.

    Article  PubMed  CAS  Google Scholar 

  54. Moul JW, Wu H, Sun L, et al.: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004, 171:1141–1147.

    Article  PubMed  Google Scholar 

  55. Seidenfeld J, Samson DJ, Hasselblad V, et al.: Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000, 132:566–577.

    PubMed  CAS  Google Scholar 

  56. Denis LJ, Keuppens F, Smith PH, et al.: Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998, 33:144–151.

    Article  PubMed  CAS  Google Scholar 

  57. Bales GT, Chodak GW: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 1996, 47:38–43; discussion 48–53.

    Article  PubMed  CAS  Google Scholar 

  58. Iversen P: Bicalutamide monotherapy for early stage prostate cancer: an update. J Urol 2003, 170:S48-S52;discussion S52–S44.

    Article  PubMed  Google Scholar 

  59. Wirth MP, See WA, McLeod DG, et al.: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004, 172:1865–1870.

    Article  PubMed  CAS  Google Scholar 

  60. Barqawi AB, Moul JW, Ziada A, et al.: Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003, 62:872–876.

    Article  PubMed  Google Scholar 

  61. Oh WK, Manola J, Bittmann L, et al.: Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 2003, 62:99–104.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Epidemiology, Columbia Presbyterian Medical Center, 161 Fort Washington Avenue, 10032-3789, New York, NY, USA

    Supriya G. Mohile MD, MS

Authors
  1. Supriya G. Mohile MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel P. Petrylak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Supriya G. Mohile MD, MS.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mohile, S.G., Petrylak, D.P. Management of asymptomatic rise in prostatic-specific antigen in patients with prostate cancer. Curr Oncol Rep 8, 213–220 (2006). https://doi.org/10.1007/s11912-006-0022-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0022-8

Keywords

Search

Navigation